Edgar Filing: QUEST DIAGNOSTICS INC

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2009
Commission file number 001-12215

Quest Diagnostics Incorporated

Three Giralda Farms
Madison, NJ 07940
(973) 520-2700

Delaware
(State of Incorporation)

16-1387862
(I.R.S. Employer Identification Number)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer x		Accelerated filer o
Non-accelerated filer o	(Do not check if a smaller reporting company)	Smaller reporting company o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes o No x

As of July 22, 2009, there were 185,747,242 outstanding shares of the registrant’s common stock, $.01 par value.

PART I - FINANCIAL INFORMATION


		Page
Item 1.	Financial Statements

	Index to consolidated financial statements filed as part of this report:

	Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2009 and 2008	2

	Consolidated Balance Sheets as of June 30, 2009 and December 31, 2008	3

	Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2009 and 2008	4

	Notes to Consolidated Financial Statements	5

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations

	Management’s Discussion and Analysis of Financial Condition and Results of Operations	28

Item 3.	Quantitative and Qualitative Disclosures About Market Risk

	See Item 2. “Management’s Discussion and Analysis of Financial Condition and Results of Operations”	35

Item 4.	Controls and Procedures

	Controls and Procedures	35

QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2009 AND 2008
(unaudited)
(in thousands, except per share data)


	Three Months Ended June 30,						Six Months Ended June 30,

	2009			2008			2009			2008


Net revenues	$	1,901,818		$	1,837,901		$	3,709,824		$	3,622,538


Operating costs and expenses:
Cost of services		1,100,212			1,083,481			2,153,701			2,142,108
Selling, general and administrative		448,756			438,037			873,057			873,115
Amortization of intangible assets		9,377			9,916			18,382			19,180
Other operating income, net		(15,902	)		(1,656	)		(15,754	)		(249	)

Total operating costs and expenses		1,542,443			1,529,778			3,029,386			3,034,154


Operating income		359,375			308,123			680,438			588,384

Other income (expense):
Interest expense, net		(36,846	)		(45,432	)		(76,254	)		(93,049	)
Equity earnings in unconsolidated joint ventures		8,382			7,592			16,952			15,591
Other (expense) income, net		(9,095	)		548			(11,804	)		(489	)

Total non-operating expenses, net		(37,559	)		(37,292	)		(71,106	)		(77,947	)


Income from continuing operations before taxes		321,816			270,831			609,332			510,437
Income tax expense		123,535			100,787			233,724			192,645

Income from continuing operations		198,281			170,044			375,608			317,792
Income (loss) from discontinued operations, net of taxes		88			(890	)		(1,583	)		(1,977	)

Net income		198,369			169,154			374,025			315,815
Less: Net income attributable to noncontrolling interests		10,169			7,826			18,723			14,880

Net income attributable to Quest Diagnostics	$	188,200		$	161,328		$	355,302		$	300,935


Amounts attributable to Quest Diagnostics’ stockholders:
Income from continuing operations	$	188,112		$	162,218		$	356,885		$	302,912
Income (loss) from discontinued operations, net of taxes		88			(890	)		(1,583	)		(1,977	)

Net income	$	188,200		$	161,328		$	355,302		$	300,935


Earnings per share attributable to Quest Diagnostics’ common stockholders - basic:
Income from continuing operations	$	1.01		$	0.83		$	1.90		$	1.56
Income (loss) from discontinued operations		—			—			(0.01	)		(0.01	)

Net income	$	1.01		$	0.83		$	1.89		$	1.55


Earnings per share attributable to Quest Diagnostics’ common stockholders - diluted:
Income from continuing operations	$	1.00		$	0.83		$	1.89		$	1.54
Income (loss) from discontinued operations		—			(0.01	)		(0.01	)		(0.01	)

Net income	$	1.00		$	0.82		$	1.88		$	1.53


Weighted average common shares outstanding:
Basic		185,266			194,527			187,318			194,335
Diluted		187,003			196,119			188,850			195,951

Dividends per common share	$	0.10		$	0.10		$	0.20		$	0.20

The accompanying notes are an integral part of these statements.

QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
JUNE 30, 2009 AND DECEMBER 31, 2008
(in thousands, except per share data)


	June 30, 2009			December 31, 2008

	(unaudited)
Assets
Current assets:
Cash and cash equivalents	$	119,294		$	253,946
Accounts receivable, net of allowance for doubtful accounts of $251,415 and $261,334 at June 30, 2009 and December 31, 2008, respectively		896,535			832,873
Inventories		79,715			102,125
Deferred income taxes		154,017			218,419
Prepaid expenses and other current assets		89,537			89,456

Total current assets		1,339,098			1,496,819
Property, plant and equipment, net		843,757			879,687
Goodwill, net		5,067,267			5,054,926
Intangible assets, net		819,320			827,403
Other assets		141,993			144,995

Total assets	$	8,211,435		$	8,403,830


Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable and accrued expenses	$	818,907		$	1,219,619
Short-term borrowings and current portion of long-term debt		204,969			5,142

Total current liabilities		1,023,876			1,224,761
Long-term debt		2,877,767			3,078,089
Other liabilities		544,150			475,846
Stockholders’ equity:
Quest Diagnostics stockholders’ equity:
Common stock, par value $0.01 per share; 600,000 shares authorized at both June 30, 2009 and December 31, 2008; 214,118 shares and 214,113 shares issued at June 30, 2009 and December 31, 2008, respectively		2,141			2,141
Additional paid-in capital		2,273,170			2,262,065
Retained earnings		2,879,722			2,561,679
Accumulated other comprehensive loss		(55,589	)		(68,068	)
Treasury stock, at cost; 28,434 shares and 23,739 shares at June 30, 2009 and December 31, 2008, respectively		(1,358,300	)		(1,152,921	)

Total Quest Diagnostics stockholders’ equity		3,741,144			3,604,896
Noncontrolling interests		24,498			20,238

Total stockholders’ equity		3,765,642			3,625,134

Total liabilities and stockholders’ equity	$	8,211,435		$	8,403,830

The accompanying notes are an integral part of these statements.

QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE SIX MONTHS ENDED JUNE 30, 2009 AND 2008
(unaudited)
(in thousands)


	Six Months Ended June 30,

	2009			2008

Cash flows from operating activities:
Net income	$	374,025		$	315,815
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		130,047			132,684
Provision for doubtful accounts		165,424			167,568
Deferred income tax provision (benefit)		57,021			(6,061	)
Stock-based compensation expense		33,166			36,841
Excess tax benefits from stock-based compensation arrangements		(1,790	)		(1,223	)
Other, net		9,525			(4,811	)
Changes in operating assets and liabilities:
Accounts receivable		(228,385	)		(213,615	)
Accounts payable and accrued expenses		4,136			(40,065	)
Integration, settlement and other special charges		(320,015	)		(4,196	)
Income taxes payable		8,067			2,187
Other assets and liabilities, net		32,335			(13,914	)

Net cash provided by operating activities		263,556			371,210


Cash flows from investing activities:
Business acquisitions, net of cash acquired		(12,052	)		19,887
Capital expenditures		(75,996	)		(94,821	)
(Increase) decrease in investments and other assets		(6,028	)		5,965

Net cash used in investing activities		(94,076	)		(68,969	)


Cash flows from financing activities:
Proceeds from borrowings		510,000			20,039
Repayments of debt		(511,185	)		(304,082	)
Decrease in book overdrafts		(19,743	)		(4,167	)
Purchases of treasury stock		(250,000	)		—
Exercise of stock options		17,225			11,562
Excess tax benefits from stock-based compensation arrangements		1,790			1,223
Dividends paid		(37,616	)		(38,889	)
Distributions to noncontrolling interests		(14,463	)		(11,834	)
Financing costs paid		(140	)		(289	)

Net cash used in financing activities		(304,132	)		(326,437	)


Net change in cash and cash equivalents		(134,652	)		(24,196	)

Cash and cash equivalents, beginning of period		253,946			167,594


Cash and cash equivalents, end of period	$	119,294		$	143,398

The accompanying notes are an integral part of these statements.

QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, unless otherwise indicated)
(unaudited)


1.	BASIS OF PRESENTATION

Background

Quest Diagnostics Incorporated and its subsidiaries (“Quest Diagnostics” or the “Company”) is the world’s leading provider of diagnostic testing, information and services, providing insights that enable patients, physicians and others to make decisions to improve health. Quest Diagnostics offers patients and physicians the broadest access to diagnostic laboratory services through the Company’s nationwide network of laboratories and patient service centers. The Company provides interpretive consultation through the largest medical and scientific staff in the industry, with approximately 900 M.D.s and Ph.D.s primarily located in the United States. Quest Diagnostics is the leading provider of clinical testing, including gene-based testing and other esoteric testing, anatomic pathology services and testing for drugs-of-abuse, and the leading provider of risk assessment services for the life insurance industry. The Company is also a leading provider of testing for clinical trials. The Company’s diagnostics products business manufactures and markets diagnostic test kits and specialized point-of-care testing. Quest Diagnostics empowers healthcare organizations and clinicians with state-of-the-art information technology solutions that can improve patient care and medical practice.

Basis of Presentation

The interim consolidated financial statements reflect all adjustments which in the opinion of management are necessary for a fair statement of financial condition and results of operations for the periods presented. Except as otherwise disclosed, all such adjustments are of a normal recurring nature. The interim consolidated financial statements have been compiled without audit. Operating results for the interim periods are not necessarily indicative of the results that may be expected for the full year. These interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company’s 2008 Annual Report on Form 10-K.

On January 1, 2009, the Company adopted Statement of Financial Accounting Standard (“SFAS”) No. 160 “Noncontrolling Interests in Consolidated Financial Statements, an Amendment of ARB No. 51” (“SFAS 160”). In accordance with the requirements of SFAS 160, the Company has provided a new presentation on the face of the consolidated financial statements to separately classify non-controlling interests within the equity section of the consolidated balance sheets and to separately report the amounts attributable to controlling and non-controlling interests in the consolidated statements of operations, comprehensive income and changes in equity for all periods presented. The adoption of SFAS 160 did not impact earnings per share attributable to Quest Diagnostics’ common stockholders.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Earnings Per Share

On January 1, 2009, the Company adopted FASB Staff Position No. EITF 03-6-1, “Determining Whether Instruments Granted in Share-Based Payment Transactions Are Participating Securities” (“FSP EITF 03-6-1”). This standard addresses whether instruments granted in share-based payment transactions are participating securities prior to vesting and, therefore, need to be included in the earnings allocation in computing earnings per share under the two-class method as described in SFAS No. 128, “Earnings per Share.” Under the guidance in FSP EITF 03-6-1, the Company’s unvested restricted common stock and unvested restricted stock units that contain non-forfeitable rights to dividends are participating securities that are included in the computation of earnings per share pursuant to the

QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED
(in thousands, unless otherwise indicated)
(unaudited)

two-class method. Earnings per share calculations for all prior periods have been presented based on the two-class method.

Basic earnings per common share is calculated by dividing net income, adjusted for earnings allocated to participating securities, by the weighted average common shares outstanding. Diluted earnings per common share is calculated by dividing net income, adjusted for earnings allocated to participating securities, by the weighted average common shares outstanding after giving effect to all potentially dilutive common shares outstanding during the period. Potentially dilutive common shares include the dilutive effect of outstanding stock options and performance share units granted under the Company’s Amended and Restated Employee Long-Term Incentive Plan and its Amended and Restated Non-Employee Director Long-Term Incentive Plan.

The computation of basic and diluted earnings per common share was as follows (in thousands, except per share data):


	Three Months Ended June 30,					Six Months Ended June 30,

	2009		2008			2009			2008

Amounts attributable to Quest Diagnostics’ stockholders:
Income from continuing operations	$	188,112	$	162,218		$	356,885		$	302,912
Income (loss) from discontinued operations		88		(890	)		(1,583	)		(1,977	)

Net income available to Quest Diagnostics’ common stockholders	$	188,200	$	161,328		$	355,302		$	300,935


Income from continuing operations	$	188,112	$	162,218		$	356,885		$	302,912
Less: Earnings allocated to participating securities		568		353			894			620

Earnings available to Quest Diagnostics’ common stockholders – basic and diluted	$	187,544	$	161,865		$	355,991		$	302,292


Weighted average common shares outstanding – basic		185,266		194,527			187,318			194,335

Effect of dilutive securities:
Stock options and performance share units		1,737		1,592			1,532			1,616

Weighted average common shares outstanding – diluted		187,003		196,119			188,850			195,951


Earnings per share attributable to Quest Diagnostics’ common stockholders - basic:
Income from continuing operations	$	1.01	$	0.83		$	1.90		$	1.56
Income (loss) from discontinued operations		—		—			(0.01	)		(0.01	)

Net income	$	1.01	$	0.83		$	1.89		$	1.55


Earnings per share attributable to Quest Diagnostics’ common stockholders - diluted:
Income from continuing operations	$	1.00	$	0.83		$	1.89		$	1.54
Income (loss) from discontinued operations		—		(0.01	)		(0.01	)		(0.01	)

Net income	$	1.00	$	0.82		$	1.88		$	1.53

Stock options and performance share units of 3.9 million shares and 4.2 million shares for the three and six months ended June 30, 2009, respectively, were not included due to their antidilutive effect.

QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED
(in thousands, unless otherwise indicated)
(unaudited)

Stock options and performance share units of 4.7 million shares and 4.4 million shares for the three and six months ended June 30, 2008, respectively, were not included due to their antidilutive effect.

Subsequent Events

The management of the Company has evaluated the period after the balance sheet date up through July 28, 2009, which is the date that the consolidated financial statements were issued, and determined that there were no subsequent events or transactions that required recognition or disclosure in the consolidated financial statements.

New Accounting Standards

On January 1, 2009, the Company adopted SFAS No. 141(R) “Business Combinations” (“SFAS 141(R)”). SFAS 141(R) changes several underlying principles in applying the acquisition method of accounting (previously referred to as the purchase method). Among the significant changes, SFAS 141(R) requires a redefining of the measurement date of a business combination, expensing direct transaction costs as incurred, capitalizing in-process research and development costs as an intangible asset and recording a liability for contingent consideration at the measurement date with subsequent re-measurements recorded in the results of operations. SFAS 141(R) also requires that costs for business restructuring and exit activities related to the acquired company will be included in the post-combination financial results of operations and also provides new guidance for the recognition and measurement of contingent assets and liabilities in a business combination. In addition, SFAS 141(R) requires several new disclosures, including the reasons for the business combination, the factors that contribute to the recognition of goodwill, the amount of acquisition related third-party expenses incurred, the nature and amount of contingent consideration, and a discussion of pre-existing relationships between the parties. Transaction costs for potential business combinations that had not closed by December 31, 2008 were written off on January 1, 2009 and were not material.

The application of SFAS 141(R) is likely to have a significant impact on how the Company allocates the purchase price of prospective business combinations, including the recognition and measurement of assets acquired and liabilities assumed and the expensing of direct transaction costs and costs to integrate the acquired business.

On January 1, 2009, the Company adopted SFAS 160 which establishes accounting and reporting standards for the non-controlling interest in a subsidiary and for the deconsolidation of a subsidiary. SFAS 160 requires entities to record the acquisition of non-controlling interests in subsidiaries initially at fair value. In accordance with the requirements of SFAS 160, the Company has provided a new presentation on the face of the consolidated financial statements to separately classify non-controlling interests within the equity section of the consolidated balance sheets and to separately report the amounts attributable to controlling and non-controlling interests in the consolidated statements of operations, comprehensive income and changes in equity for all periods presented. The adoption of SFAS 160 did not impact earnings per share attributable to Quest Diagnostics’ common stockholders. There were no changes in the Company’s ownership interests in subsidiaries or deconsolidation of subsidiaries for the three or six months ended June 30, 2009.

On January 1, 2009, the Company adopted SFAS No. 161 “Disclosures About Derivative Instruments and Hedging Activities – an amendment of FASB Statement No. 133” (“SFAS 161”). SFAS 161 amends SFAS No. 133, “Accounting for Derivative Instruments and Hedging Activities,” by requiring expanded disclosures about an entity’s derivative instruments and hedging activities. SFAS 161 requires qualitative disclosures about objectives and strategies for using derivatives, quantitative disclosures about fair value amounts of and gains and losses on derivative instruments, and disclosures about credit-risk-related contingent features in derivative instruments.

QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED
(in thousands, unless otherwise indicated)
(unaudited)

Fair Value of Financial Instruments” (“SFAS 107”), to interim period financial statements, in addition to the existing requirements for annual periods and reiterates SFAS 107’s requirement to disclose the methods and significant assumptions used to estimate fair value. FSP FAS 107-1 and APB 28-1 was effective for the Company’s interim and annual periods commencing with its June 30, 2009 consolidated financial statements and have been applied on a prospective basis. FSP FAS 107-1 and APB 28-1 did not have a material impact on the Company’s consolidated financial statements.

In June 2009, the FASB issued SFAS No. 165, “Subsequent Events” (“SFAS 165”). Prior to SFAS 165, the authoritative guidance for subsequent events was previously addressed only in U.S. auditing standards. SFAS 165 establishes general standards of accounting for and disclosure of events that occur after the balance sheet date but before financial statements are issued or are available to be issued and requires the Company to disclose the date through which it has evaluated subsequent events and whether that was the date the financial statements were issued or available to be issued. SFAS 165 does not apply to subsequent events or transactions that are within the scope of other applicable generally accepted accounting principles in the United States (“GAAP”) that provide different guidance on the accounting treatment for subsequent events or transactions. SFAS 165 became effective for the Company on June 30, 2009 and its adoption did not have a material impact on its consolidated financial statements.

In June 2009, the FASB issued SFAS No. 167, “Amendments to FASB Interpretation No. 46(R)” (“SFAS 167”). SFAS 167 amends FIN 46(R) to provide a new approach for determining which entity should consolidate a variable interest entity (VIE), how and when to reconsider the consolidation or de-consolidation of a VIE and requires disclosures about an entity’s significant judgments and assumptions used in its decision to consolidate or not consolidate a VIE. Under SFAS 167, the new consolidation model is a more qualitative assessment of power and economics that considers which entity has the power to direct the activities that “most significantly impact” the VIE’s economic performance and has the obligation to absorb losses or the right to receive benefits that could be potentially significant to the VIE. SFAS 167 is effective for the Company as of January 1, 2010 and the Company does not expect the impact of its adoption to be material to its consolidated financial statements.


2.	FAIR VALUE MEASUREMENTS

SFAS No. 157, “Fair Value Measurements” (“SFAS 157”) provides a single definition of fair value and a common framework for measuring fair value as well as new disclosure requirements for fair value measurements used in financial statements. Fair value measurements are based upon the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants exclusive of any transaction costs, and are determined by either the principal market or the most advantageous market. The principal market is the market with the greatest level of activity and volume for the asset or liability. Absent a principal market to measure fair value, the Company has used the most advantageous market, which is the market that the Company would receive the highest selling price for the asset or pay the lowest price to settle the liability, after considering transaction costs. However, when using the most advantageous market, transactions costs are only considered to determine which market is the most advantageous and these costs are then excluded when applying a fair value measurement.

On January 1, 2009, the Company adopted the provisions of SFAS 157 for applying fair value measurements to assets, liabilities and transactions on a non-recurring basis and the adoption did not have a material effect on the Company’s financial position, results of operations or cash flows.

SFAS 157 creates a three-level hierarchy to prioritize the inputs used in the valuation techniques to derive fair values. The basis for fair value measurements for each level within the hierarchy is described below with Level 1 having the highest priority and Level 3 having the lowest.

Level 1: Quoted prices in active markets for identical assets or liabilities.

QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED
(in thousands, unless otherwise indicated)
(unaudited)

Level 2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets.

Level 3: Valuations derived from valuation techniques in which one or more significant inputs are unobservable.

The following table provides a summary of the recognized assets and liabilities that are measured at fair value on a recurring basis.


			Basis of Fair Value Measurements

			Quoted Prices in Active Markets for Identical Assets / Liabilities		Significant Other Observable Inputs		Significant Unobservable Inputs

	June 30, 2009		Level 1		Level 2		Level 3

Assets:
Trading securities	$	27,297	$	27,297	$	—	$	—
Cash surrender value of life insurance policies		13,272		—		13,272		—
Foreign currency forward contracts		1,138		—		1,138		—

Total	$	41,707	$	27,297	$	14,410	$	—


Liabilities:
Deferred compensation liabilities	$	43,682	$	—	$	43,682	$	—
Interest rate swaps		3,923		—		3,923		—
Foreign currency forward contracts		674		—		674		—

Total	$	48,279	$	—	$	48,279	$	—

The Company offers certain employees the opportunity to participate in a supplemental deferred compensation plan. A participant’s deferrals, together with Company matching credits, are invested in a variety of participant-directed stock and bond mutual funds as well as Company common stock and are classified as trading securities. Changes in the fair value of these securities are measured using quoted prices in active markets based on the market price per unit multiplied by the number of units held exclusive of any transaction costs. A corresponding adjustment for changes in fair value of the trading securities is also reflected in the changes in fair value of the deferred compensation obligation. The deferred compensation liabilities are classified within Level 2 because their inputs are derived principally from observable market data by correlation to the trading securities.

In connection with the acquisition of AmeriPath Group Holdings, Inc. (“AmeriPath”) in May 2007, the Company assumed a non-qualified deferred compensation program AmeriPath offers to certain employees. A participant’s deferrals, together with Company matching credits, are “invested” at the direction of the employee in a hypothetical portfolio of investments which are tracked by an administrator. The Company purchases life insurance policies, with the Company named as beneficiary of the policies, for the purpose of funding the program’s liability. Changes in the cash surrender value of the life insurance policies are based upon earnings and changes in the value of the underlying investments. Changes in the fair value of the deferred compensation obligation are derived using quoted prices in active markets based on the market price per unit multiplied by the number of units. The cash surrender value and the deferred compensation obligations are classified within Level 2 because their inputs are derived principally from observable market data by correlation to the hypothetical investments.

QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED
(in thousands, unless otherwise indicated)
(unaudited)

The fair value measurements of foreign currency forward contracts are obtained from a third-party pricing service. The fair value measurements of the Company’s interest rate swaps are model-derived valuations as of a given date in which all significant inputs are observable in active markets including certain financial information and certain assumptions regarding past, present and future market conditions. The Company does not believe that the changes in the fair values of its foreign currency forward contracts and interest rate swaps will materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on its results of operations, liquidity and capital resources.

In June 2009, the Company recorded a charge of $7.0 million associated with the write-down of an investment due to the uncertainty of recoverability from an other-than-temporary impairment loss. A fair value measurement, using significant unobservable inputs, has been applied to this asset on a non-recurring basis.

The carrying amounts of cash and cash equivalents, accounts receivable and accounts payable and accrued expenses approximate fair value based on the short maturities of these instruments. In accordance with the provisions of SFAS 107, at June 30, 2009 and December 31, 2008, the fair value of the Company’s debt was estimated at approximately $3.1 billion and $2.9 billion, respectively, using quoted market prices and yields for the same or similar types of borrowings, taking into account the underlying terms of the debt instruments. At June 30, 2009, the estimated fair value exceeded the carrying value of the debt by $31 million. At December 31, 2008, the carrying value exceeded the estimated fair value of the debt by $155 million.


3.	GOODWILL AND INTANGIBLE ASSETS

The changes in goodwill, net for the six months ended June 30, 2009 and for the year ended December 31, 2008 are as follows:


	June 30, 2009			December 31, 2008


Balance at beginning of period	$	5,054,926		$	5,220,104
Goodwill acquired during the year		8,242			9,260
Other purchase accounting adjustments		(323	)		(120,105	)
Increase (decrease) related to foreign currency translation		4,422			(54,333	)

Balance at end of period	$	5,067,267		$	5,054,926

Approximately 90% of the Company’s goodwill as of June 30, 2009 and December 31, 2008 was associated with its clinical testing business.

For the six months ended June 30, 2009 and for the year ended December 31, 2008, goodwill acquired during the year was associated with several immaterial acquisitions. For the year ended December 31, 2008, other purchase accounting adjustments were primarily due to changes in estimates regarding the realization of certain pre-acquisition net operating loss carryforwards, the reduction in certain acquired pre-acquisition tax loss contingencies, and a payment received in 2008 from an escrow fund established at the time of an acquisition in 2007.

QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED
(in thousands, unless otherwise indicated)
(unaudited)

Intangible assets at June 30, 2009 and December 31, 2008 consisted of the following:


	Weighted Average Amortization Period	June 30, 2009							December 31, 2008


		Cost		Accumulated Amortization			Net		Cost		Accumulated Amortization			Net

Amortizing intangible assets:
Customer-related intangibles	19 years	$	588,254	$	(114,354	)	$	473,900	$	585,963	$	(99,384	)	$	486,579
Non-compete agreements	5 years		54,553		(49,256	)		5,297		54,382		(48,298	)		6,084
Other	12 years		61,225		(15,990	)		45,235		53,934		(13,258	)		40,676

Total	19 years		704,032		(179,600	)		524,432		694,279		(160,940	)		533,339

Intangible assets not subject to amortization:
Tradenames			294,888		—			294,888		294,064		—			294,064


Total intangible assets		$	998,920	$	(179,600	)	$	819,320	$	988,343	$	(160,940	)	$	827,403

Amortization expense related to intangible assets was $9.4 million and $9.9 million for the three months ended June 30, 2009 and 2008, respectively. For the six months ended June 30, 2009 and 2008, amortization expense related to intangible assets was $18.4 million and $19.2 million, respectively.

The estimated amortization expense related to intangible assets for each of the five succeeding fiscal years and thereafter as of June 30, 2009 is as follows:


Fiscal Year Ending December 31,


Remainder of 2009	$	18,609
2010		36,962
2011		36,699
2012		35,412
2013		34,415
2014		33,373
Thereafter		328,962


Total	$	524,432


4.	FINANCIAL INSTRUMENTS

The Company uses derivative financial instruments to manage its exposure to market risks for changes in interest rates and foreign currency. This includes the use of interest rate swap agreements and foreign currency forward contracts to manage its exposure to movements in interest and currency rates. The Company has established policies and procedures for risk assessment and the approval, reporting and monitoring of derivative financial instrument activities. These policies prohibit holding or issuing derivative financial instruments for speculative or trading purposes. The Company does not enter into derivative financial instruments that contain credit-risk-related contingent features or requirements to post collateral.

QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED
(in thousands, unless otherwise indicated)
(unaudited)

Interest Rate Risk

The Company is exposed to interest rate risk on its cash and cash equivalents and its debt obligations. Interest income earned on cash and cash equivalents may fluctuate as interest rates change, however, due to their relatively short maturities, the Company does not hedge these assets and the impact of interest rate risk is not material. The Company’s debt obligations consist of fixed-rate and variable-rate debt instruments. The Company’s objective is to mitigate the variability in cash outflows that result from changes in interest rates by maintaining a balanced mix of fixed-rate and variable-rate debt obligations. In order to achieve these objectives, the Company has entered into interest rate swaps on a portion of one of its variable-rate debt obligations to make that portion a fixed-rate debt instrument. As of June 30, 2009, the interest rate swaps allowed the Company to receive variable rates of interest based on three-month LIBOR plus an agreed upon spread of 50 basis points and pay fixed rates of interest ranging from 5.13% to 5.27% on notional amounts aggregating $200 million. As of June 30, 2009, the three-month LIBOR rate on these financial instruments was 1.05%. These interest rate swaps are accounted for as cash flow hedges and the Company records the derivatives as either an asset or liability measured at its fair value. The effective portion of changes in the fair value of the derivatives is recorded in “accumulated other comprehensive loss.” If it is determined that a derivative ceases to be a highly effective hedge, the Company discontinues hedge accounting, and any deferred gains or losses are recorded in the consolidated statement of operations. The total loss, net of tax benefit, recognized in accumulated other comprehensive loss on the interest rate swaps as of June 30, 2009 and December 31, 2008 was $2.4 million and $3.6 million, respectively. There was no gain or loss recognized on the swap agreements for the three or six months ended June 30, 2009 and 2008 as a result of ineffectiveness. The periodic net cash settlements under the interest rate swaps are recorded in interest expense, net.

Foreign Currency Risk

The Company is exposed to market risk for changes in foreign exchange rates primarily under certain inter-company receivables and payables. Foreign exchange forward contracts are used to mitigate the exposure of the eventual net cash inflows or outflows resulting from these intercompany transactions. The objective is to hedge a portion of the forecasted foreign currency risk over a rolling 12-month time horizon to mitigate the eventual impacts of changes in foreign exchange rates on the cash flows of the intercompany transactions. As of June 30, 2009, the total notional amount of foreign currency forward contracts in U.S. dollars was $49.5 million and principally consist of contracts in Swedish krona and British pounds. Notional amounts represent the face amount of contractual arrangements and the basis on which currencies are exchanged and are not a measure of market or credit risk exposure. The Company does not designate these derivative instruments as hedges under current accounting standards unless the benefits of doing so are material. The Company’s foreign exchange exposure is not material to the Company’s consolidated financial condition or results of operations. The Company does not hedge its net investment in non-U.S. subsidiaries because it views those investments as long-term in nature.

QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED
(in thousands, unless otherwise indicated)
(unaudited)

A summary of the fair values of derivative instruments in the consolidated balance sheets is stated in the table below (in thousands):


	June 30, 2009				December 31, 2008


	Balance Sheet Classification		Fair Value		Balance Sheet Classification		Fair Value


Derivatives Designated as Hedging Instruments
Liability Derivatives:
Interest rate swaps		Other current liabilities	$	3,923		Other current liabilities	$	5,888

Total				3,923				5,888


Derivatives Not Designated as Hedging Instruments
Asset Derivatives:

Foreign currency forward contracts		Other current assets		1,138		Other current assets		2,617

Total				1,138				2,617


Liability Derivatives:
Foreign currency forward contracts		Other current liabilities		674		Other current liabilities		4,142

Total				674				4,142


Total Net Derivatives Liability			$	3,459			$	7,413


5.	DEBT

Short-term borrowings and current portion of long-term debt at June 30, 2009 and December 31, 2008 consisted of the following:


	June 30, 2009		December 31, 2008


Borrowings under Secured Receivables Credit Facility	$	200,000	$	—
Current portion of long-term debt		4,969		5,142

Total short-term borrowings and current portion of long-term debt	$	204,969	$	5,142

QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED
(in thousands, unless otherwise indicated)
(unaudited)

Long-term debt at June 30, 2009 and December 31, 2008 consisted of the following:


	June 30, 2009		December 31, 2008


Industrial Revenue Bonds due September 2009	$	1,800	$	1,800
Senior Notes due November 2010		226,243		399,724
Senior Notes due July 2011		248,432		274,724
Term Loan due May 2012		1,092,000		1,092,000
Senior Notes due November 2015		498,987		498,907
Senior Notes due July 2017		374,361		374,320
Senior Notes due July 2037		420,604		420,526
Debentures due June 2034		3,098		3,070
Other		17,211		18,160

Total		2,882,736		3,083,231
Less: current portion		4,969		5,142

Total long-term debt	$	2,877,767	$	3,078,089

June 2009 Debt Tender

On May 19, 2009, the Company commenced a cash tender offer to purchase up to $200 million aggregate principal amount of its 5.125% Senior Notes due 2010 and 7.50% Senior Notes due 2011 (collectively, the “Notes”). On June 16, 2009, the Company finalized its cash tender offer (the “June 2009 Debt Tender”) by purchasing approximately $174 million aggregate principal amount of its 5.125% Senior Notes Due 2010 and approximately $26 million aggregate principal amount of its 7.50% Senior Notes due 2011 that resulted in pre-tax losses of $4.8 million and $1.5 million, respectively. The aggregate pre-tax loss of $6.3 million includes the write-off of $0.5 million of deferred financing fees and unamortized discounts and cash payments of $5.8 million related to premiums and other costs to purchase the Notes and is included in “other (expense) income, net.” The June 2009 Debt Tender was financed with cash on-hand and $150 million of borrowings under the Secured Receivables Credit Facility.

Secured Receivables Credit Facility

For the six months ended June 30, 2009, the Company borrowed $510 million under its Secured Receivables Credit Facility primarily to fund second quarter payments totaling $308 million in connection with the previously disclosed settlement of the federal government investigation related to NID (see Note 8) and to fund $150 million of debt repayments in connection with the June 2009 Debt Tender. During the six months ended June 30, 2009, the Company repaid $310 million on its Secured Receivables Credit Facility. At June 30, 2009, borrowings outstanding under the Secured Receivables Credit Facility totaled $200 million.

As of June 30, 2009, long-term debt maturing in each of the years subsequent to June 30, 2010 is as follows:


Fiscal Year ending December 31,

2010	$	226,243
2011		782,064
2012		561,357
2013		617
2014		263
2015		499,266
Thereafter		807,957

Total long-term debt	$	2,877,767

A full description of the terms of the Company’s indebtedness and related debt service requirements is contained in Note 9 to the Consolidated Financial Statements in the Company’s 2008 Annual Report on Form 10-K.

QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED
(in thousands, unless otherwise indicated)
(unaudited)


6.	STOCKHOLDERS’ EQUITY

Changes in stockholders’ equity for the six months ended June 30, 2009 were as follows:


	Quest Diagnostics Stockholders’ Equity

	Shares of Common Stock Outstand- ing		Common Stock		Additional Paid-In Capital			Retained Earnings			Accumulated Other Compre- hensive Loss			Treasury Stock, at Cost			Compre- hensive Income		Noncontroll- ing Interests			Total Stockholders’ Equity

*Balance, December 31, 2008*	190,374		$	2,141	$	2,262,065		$	2,561,679		$	(68,068	)	$	(1,152,921	)			$	20,238		$	3,625,134
Net income									355,302								$	355,302		18,723			374,025
Currency translation												10,955						10,955					10,955
Reversal of market valuation, net of tax expense of $190												290						290					290
Deferred loss, less reclassifications												1,234						1,234					1,234

Comprehensive income																	$	367,781

Dividends declared									(37,259	)													(37,259	)
Distributions to noncontrolling interests																				(14,463	)		(14,463	)
Issuance of common stock under benefit plans	500					368									9,402								9,770
Stock-based compensation expense						20,878									12,288								33,166
Exercise of stock options	559					(9,701	)								26,926								17,225
Shares to cover employee payroll tax withholdings on stock issued under benefit plans	(129	)				(1,822	)								(3,995	)							(5,817	)
Tax benefits associated with stock-based compensation plans						1,382																	1,382
Purchases of treasury stock	(5,620	)													(250,000	)							(250,000	)

*Balance, June 30, 2009*	185,684		$	2,141	$	2,273,170		$	2,879,722		$	(55,589	)	$	(1,358,300	)			$	24,498		$	3,765,642

For the three months ended June 30, 2009, total comprehensive income was $220 million.

The market valuation adjustment represents the reversal of prior period unrealized holding losses for investments, net of taxes, where the decline in fair value was deemed to be other than temporary and the resulting loss was recognized in the consolidated statement of operations. The deferred loss primarily represents deferred losses on the Company’s interest rate swap agreements, net of amounts reclassified to interest expense. Foreign currency translation adjustments are not adjusted for income taxes since they relate to indefinite investments in non-U.S. subsidiaries.

Dividend Program

During each of the quarters of 2009 and 2008, the Company’s Board of Directors has declared a quarterly cash dividend of $0.10 per common share.

QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED
(in thousands, unless otherwise indicated)
(unaudited)

Share Repurchase Plan

In January 2009, the Company’s Board of Directors authorized the Company to repurchase an additional $500 million of the Company’s common stock. The share repurchase authorization has no set expiration or termination date.

The Company did not purchase any shares of its common stock during the second quarter of 2009. For the six months ended June 30, 2009, the Company repurchased approximately 5.6 million shares of its common stock at an average price of $44.48 per share for $250 million, including 4.5 million shares repurchased from SB Holdings Capital Inc., a wholly-owned subsidiary of GlaxoSmithKline plc., at an average price of $44.33 per share for $200 million. For the three and six months ended June 30, 2009, the Company reissued 0.4 million shares and 0.9 million shares, respectively, for employee benefit plans. At June 30, 2009, $250 million of share repurchase authorization remained available.

Changes in stockholders’ equity for the six months ended June 30, 2008 were as follows:


	Quest Diagnostics Stockholders’ Equity

	Shares of Common Stock Outstand- ing		Common Stock		Additional Paid-In Capital			Retained Earnings			Accumulated Other Compre- hensive Income (Loss)			Treasury Stock, at Cost			Compre- hensive Income			Noncontroll- ing Interests			Total Stockholders’ Equity

*Balance, December 31, 2007*	194,040		$	2,137	$	2,210,825		$	2,057,744		$	25,279		$	(971,743	)				$	21,463		$	3,345,705
Net income									300,935								$	300,935			14,880			315,815
Currency translation												26,818						26,818						26,818
Market valuation, net of tax benefit of $2,269												(3,461	)					(3,461	)					(3,461	)
Deferred loss, less reclassifications												(1,685	)					(1,685	)					(1,685	)

Comprehensive income																	$	322,607

Dividends declared									(38,949	)														(38,949	)
Distributions to noncontrolling interests																					(11,834	)		(11,834	)
Issuance of common stock under benefit plans	693			4		(21	)								9,326									9,309
Stock-based compensation expense						30,909									5,932									36,841
Exercise of stock options	397					(8,023	)								19,585									11,562
Shares to cover employee payroll tax withholdings on stock issued under benefit plans	(50	)				(687	)								(1,614	)								(2,301	)
Tax benefits associated with stock-based compensation plans						4,009																		4,009
Other						334																		334

*Balance, June 30, 2008*	195,080		$	2,141	$	2,237,346		$	2,319,730		$	46,951		$	(938,514	)				$	24,509		$	3,692,163

For the three months ended June 30, 2008 comprehensive income was $157 million.

The market valuation adjustment represents unrealized holding losses on investments, net of taxes. The deferred loss primarily represents deferred losses on the Company’s interest rate swap agreements, net of amounts reclassified to interest expense. Foreign currency translation adjustments are not adjusted for income taxes since they relate to indefinite investments in non-U.S. subsidiaries.

QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED
(in thousands, unless otherwise indicated)
(unaudited)

For the three and six months ended June 30, 2008, the Company reissued 0.3 million shares and 0.7 million shares, respectively, for employee benefit plans. The Company did not purchase any shares of its common stock during the three or six months ended June 30, 2008.


7.	SUPPLEMENTAL CASH FLOW & OTHER DATA


	Three Months Ended June 30,						Six Months Ended June 30,

	2009			2008			2009			2008


Depreciation expense	$	55,811		$	57,509		$	111,665		$	113,504

Interest expense		(36,961	)		(46,876	)		(76,805	)		(96,521	)
Interest income		115			1,444			551			3,472

Interest expense, net		(36,846	)		(45,432	)		(76,254	)		(93,049	)

Interest paid		29,720			40,702			76,857			99,631
Income taxes paid		136,153			168,371			167,500			193,213


8.	COMMITMENTS AND CONTINGENCIES

The Company has a line of credit with a financial institution totaling $85 million for the issuance of letters of credit (the “letter of credit line”). The letter of credit line, which is renewed annually, matures on November 19, 2009 and is guaranteed by certain of the Company’s domestic, wholly-owned subsidiaries (the “Subsidiary Guarantors”).

In support of its risk management program, to ensure the Company’s performance or payment to third parties, $74 million in letters of credit were outstanding at June 30, 2009. The letters of credit primarily represent collateral for current and future automobile liability and workers’ compensation loss payments. In addition, $5.4 million of bank guarantees were outstanding at June 30, 2009 in support of certain foreign operations.

Contingent Lease Obligations

The Company is subject to contingent obligations under certain leases and other instruments incurred in connection with real estate activities and other operations associated with LabOne, Inc., which the Company acquired in 2005, and certain of its predecessor companies. No liability has been recorded for any of these potential contingent obligations. See Note 14 to the Consolidated Financial Statements contained in the Company’s 2008 Annual Report on Form 10-K for further details.

Legal Matters

The Company is involved in various legal proceedings. Some of the proceedings against the Company involve claims that are substantial in amount.

NID Investigation

On April 15, 2009, the Company finalized the resolution of the previously disclosed federal government investigation related to NID, a test kit subsidiary voluntarily closed in 2006, and entered into a final settlement agreement with the federal government. Pursuant to the settlement agreement, in the second quarter of 2009, the Company paid $268 million to settle the civil allegations. As part of the settlement agreement, the Company was released from all federal civil claims underlying the investigation and the United States Department of Health and

QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED
(in thousands, unless otherwise indicated)
(unaudited)

Human Services agreed to refrain from seeking the Company’s exclusion from Medicare, Medicaid or other federal healthcare programs. The Company also entered into a five-year corporate integrity agreement with the Office of Inspector General for the United States Department of Health and Human Services. In addition, NID pled guilty to a single count of felony misbranding and paid a $40 million fine. These second quarter payments totaling $308 million, which had been previously reserved, were funded out of cash on-hand and available credit facilities. The Company also expects to enter into separate settlement agreements with certain states totaling approximately $6 million which are fully reserved for.

In June 2009, a shareholder plaintiff filed a purported derivative action in the Superior Court of New Jersey, Morris County, on behalf of the Company against certain present and former directors and officers of the Company based on, among other things, their alleged breaches of fiduciary duties in connection with the manufacture, marketing, sale and billing related to certain test kits manufactured by NID. The complaint includes claims for, among other things, breach of fiduciary duty and waste of corporate assets and seeks, among other things, damages and remission of compensation received by the individual defendants.

Other Matters

The Company has in the past entered into several settlement agreements with various government and private payers relating to industry-wide billing and marketing practices that had been substantially discontinued. The federal or state governments may bring additional claims based on new theories as to the Company’s practices which management believes to be in compliance with law. In addition, certain federal and state statutes, including the qui tam provisions of the federal False Claims Act, allow private individuals to bring lawsuits against healthcare companies on behalf of government or private payers alleging inappropriate billing practices. The Company is aware of certain pending lawsuits, including a class action lawsuit, and has received several subpoenas related to billing practices.

During the second quarter of 2005, the Company received a subpoena from the United States Attorney’s Office for the District of New Jersey. The subpoena seeks the production of business and financial records regarding capitation and risk sharing arrangements with government and private payers for the years 1993 through 1999. Also, during the third quarter of 2005, the Company received a subpoena from the United States Department of Health and Human Services, Office of the Inspector General. The subpoena seeks the production of various business records including records regarding the Company’s relationship with health maintenance organizations, independent physician associations, group purchasing organizations, and preferred provider organizations relating back to as early as 1995. The Company is cooperating with the United States Attorney’s Office and the Office of the Inspector General.

In 2006 and 2008, the Company and several of its subsidiaries received subpoenas from the California Attorney General’s Office seeking documents relating to the Company’s billings to MediCal, the California Medicaid program. The Company cooperated with the government’s requests. Subsequently, the State of California intervened as plaintiff in a civil lawsuit, California ex rel. Hunter Laboratories, LLC v. Quest Diagnostics Incorporated., et al., filed in California Superior Court against a number of clinical laboratories, including the Company and several of its subsidiaries. The complaint alleges overcharging of MediCal for testing services. The complaint was originally filed by a competitor laboratory in California under the whistleblower provisions of the California False Claims Act. The complaint was unsealed on March 20, 2009.

In April 2009, the Company and certain of its subsidiaries received a subpoena from the Virginia Attorney General’s Office seeking documents related to the Company’s billings to the Virginia Medicaid program. The Company is cooperating with the request.

The Company understands that there may be other pending qui tam claims brought by former employees or other “whistle blowers” as to which the Company cannot determine the extent of any potential liability. The Company also is aware of certain pending individual or class action lawsuits related to billing practices filed under the qui tam provisions of the Civil False Claims Act and/or other federal and state statutes, regulations or other laws.

QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED
(in thousands, unless otherwise indicated)
(unaudited)

Several of these other matters are in their early stages of development and involve responding to and cooperating with various government investigations and related subpoenas. While the Company believes that at least a reasonable possibility exists that losses may have been incurred, based on the nature and status of the investigations, the losses are either currently not probable or cannot be reasonably estimated.

Management has established reserves in accordance with generally accepted accounting principles for the other matters discussed above. Such reserves totaled less than $5 million as of June 30, 2009. Although management cannot predict the outcome of such matters, management does not anticipate that the ultimate outcome of such matters will have a material adverse effect on the Company’s financial condition but may be material to the Company’s results of operations or cash flows in the period in which the impact of such matters is determined or paid. In addition, there may be pending qui tam claims brought by former employees or other “whistle blowers,” or other pending claims as to which the Company has not been provided with a copy of the complaint and accordingly cannot determine the extent of any potential liability.

As a general matter, providers of clinical testing services may be subject to lawsuits alleging negligence or other similar legal claims. These suits could involve claims for substantial damages. Any professional liability litigation could also have an adverse impact on the Company’s client base and reputation. The Company maintains various liability insurance coverage for claims that could result from providing or failing to provide clinical testing services, including inaccurate testing results and other exposures. The Company’s insurance coverage limits its maximum exposure on individual claims; however, the Company is essentially self-insured for a significant portion of these claims. Reserves for such matters are established by considering actuarially determined losses based upon the Company’s historical and projected loss experience. Management believes that present insurance coverage and reserves are sufficient to cover currently estimated exposures. Although management cannot predict the outcome of any claims made against the Company, management does not anticipate that the ultimate outcome of any such proceedings or claims will have a material adverse effect on the Company’s financial condition but may be material to the Company’s results of operations or cash flows in the period in which the impact of such claims is determined or paid.


9.	DISCONTINUED OPERATIONS

During the fourth quarter of 2005, NID instituted its second voluntary product hold within a six-month period due to quality issues, which adversely impacted the operating performance of NID. As a result, the Company evaluated a number of strategic options for NID. On April 19, 2006, the Company decided to discontinue NID’s operations. During the third quarter of 2006, the Company completed its wind down of NID and classified the operations of NID as discontinued operations. Results of operations for NID have been reported as discontinued operations in the accompanying consolidated statements of operations and related disclosures for all periods presented.

During the third quarter of 2007, the government and the Company began settlement discussions with respect to the government’s investigation involving NID and the Company. Based on the status of settlement discussions, during 2007 the Company established a reserve, in accordance with generally accepted accounting principles, reflected in discontinued operations, of $241 million in connection with these claims.

During the third quarter of 2008, the Company and NID reached an agreement in principle with the United States Attorney’s Office to settle the federal government investigation involving NID and the Company regarding NID test kits and tests performed using those test kits. As a result of the agreement in principle in 2008, the Company recorded charges of $75 million in discontinued operations to increase its reserve for the settlement and related matters.

On April 15, 2009, the Company finalized the resolution of the federal government investigation related to NID and entered into a final settlement agreement with the federal government. In the second quarter of 2009, the Company paid $268 million to settle the civil allegations. In addition, NID pled guilty to a single count of felony misbranding and paid a $40 million fine. These second quarter payments totaling $308 million, which had been previously reserved, were funded out of cash on-hand and available credit facilities. The Company also

QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED
(in thousands, unless otherwise indicated)
(unaudited)

expects to enter into separate settlement agreements with certain states totaling approximately $6 million which are fully reserved for. See Note 8 for further details.

Summarized financial information for the discontinued operations of NID is set forth below:


	Three Months Ended June 30,						Six Months Ended June 30,

	2009			2008			2009			2008


Net revenues	$	—		$	—		$	—		$	—

Income (loss) from discontinued operations before income taxes		148			(1,500	)		(2,672	)		(3,093	)
Income tax (expense) benefit		(60	)		610			1,089			1,116

Income (loss) from discontinued operations, net of taxes	$	88		$	(890	)	$	(1,583	)	$	(1,977	)

At June 30, 2009 and December 31, 2008, the settlement reserve totaling $7 million and $316 million, respectively, is included in “accounts payable and accrued expenses” in the consolidated balance sheet. The deferred tax asset recorded in connection with establishing the reserve of $58 million is included in “deferred income taxes” in the consolidated balance sheet at December 31, 2008. The remaining balance sheet information related to NID was not material at June 30, 2009 and December 31, 2008.


10.	BUSINESS SEGMENT INFORMATION

Clinical testing is an essential element in the delivery of healthcare services. Physicians use clinical tests to assist in the detection, diagnosis, evaluation, monitoring and treatment of diseases and other medical conditions. Clinical testing is generally categorized as clinical laboratory testing and anatomic pathology services. Clinical laboratory testing is performed on blood and body fluids, such as urine. Anatomic pathology services are performed on tissues, such as biopsies, and other samples, such as human cells. Customers of the clinical testing business include patients, physicians, hospitals, employers, governmental institutions and other commercial clinical laboratories. The clinical testing business accounted for greater than 90% of net revenues from continuing operations in 2009 and 2008.

All other operating segments include the Company’s non-clinical testing businesses and consist of its risk assessment services business, its clinical trials testing business, its healthcare information technology business, MedPlus and its diagnostics products businesses. The Company’s risk assessment business provides underwriting support services to the life insurance industry including teleunderwriting, paramedical examinations, laboratory testing and medical record retrieval. The Company’s clinical trials testing business provides clinical testing performed in connection with clinical research trials on new drugs and vaccines. MedPlus is a developer and integrator of clinical connectivity and data management solutions for healthcare organizations, physicians and clinicians. The Company’s diagnostics products business manufactures and markets diagnostic test kits.

On April 19, 2006, the Company decided to discontinue NID’s operations and results of operations for NID have been classified as discontinued operations for all years presented (see Note 9).

At June 30, 2009, substantially all of the Company’s services are provided within the United States, and substantially all of the Company’s assets are located within the United States.

The following table is a summary of segment information for the three and six months ended June 30, 2009 and 2008. Segment asset information is not presented since it is not reported to or used by the chief operating decision maker at the operating segment level. Operating earnings (loss) of each segment represents net revenues less directly identifiable expenses to arrive at operating income for the segment. General management and administrative corporate expenses, including amortization of intangible assets, are included in general corporate

QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED
(in thousands, unless otherwise indicated)
(unaudited)

expenses below. The accounting policies of the segments are the same as those of the Company as set forth in Note 2 to the Consolidated Financial Statements contained in the Company’s 2008 Annual Report on Form 10-K and Note 1 to the interim consolidated financial statements.


	Three Months Ended June 30,						Six Months Ended June 30,

	2009			2008			2009			2008

Net revenues:
Clinical laboratory testing business	$	1,742,292		$	1,675,530		$	3,405,924		$	3,303,633
All other operating segments		159,526			162,371			303,900			318,905

Total net revenues	$	1,901,818		$	1,837,901		$	3,709,824		$	3,622,538


Operating earnings (loss):
Clinical laboratory testing business	$	393,524	(a)	$	337,938		$	736,935	(a)	$	643,902
All other operating segments		20,302			14,050			33,165			22,692
General corporate expenses		(54,451	)		(43,865	)		(89,662	)		(78,210	)

Total operating income		359,375			308,123			680,438			588,384
Non-operating expenses, net		(37,559	) (b)		(37,292	)		(71,106	) (b)		(77,947	)

Income from continuing operations before income taxes		321,816			270,831			609,332			510,437
Income tax expense		123,535			100,787			233,724			192,645

Income from continuing operations		198,281			170,044			375,608			317,792
Income (loss) from discontinued operations, net of taxes		88			(890	)		(1,583	)		(1,977	)

Net income		198,369			169,154			374,025			315,815
Less: Net income attributable to noncontrolling interests		10,169			7,826			18,723			14,880

Net income attributable to Quest Diagnostics	$	188,200		$	161,328		$	355,302		$	300,935


	(a)	For the three and six months ended June 30, 2009, operating income includes a $15.5 million gain associated with an insurance settlement for storm related losses.

	(b)	For the three and six months ended June 30, 2009, non-operating expenses, net includes a $7.0 million charge related to the write-off of an investment and a $6.3 million loss on the early extinguishment of debt (see Note 5 for further details).

QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED
(in thousands, unless otherwise indicated)
(unaudited)


11.	SUMMARIZED FINANCIAL INFORMATION

The Company’s senior notes due 2010, senior notes due 2011, senior notes due 2015, senior notes due 2017 and senior notes due 2037 are fully and unconditionally guaranteed by the Subsidiary Guarantors. With the exception of Quest Diagnostics Receivables Incorporated (see paragraph below), the non-guarantor subsidiaries are primarily foreign subsidiaries and less than wholly-owned subsidiaries.

In conjunction with the Company’s secured receivables credit facility, the Company maintains a wholly-owned non-guarantor subsidiary, Quest Diagnostics Receivables Incorporated (“QDRI”). The Company and certain of its Subsidiary Guarantors transfer certain domestic receivables to QDRI. QDRI utilizes the transferred receivables to collateralize borrowings under the Company’s secured receivables credit facility. The Company and the Subsidiary Guarantors provide collection services to QDRI. QDRI uses cash collections principally to purchase new receivables from the Company and the Subsidiary Guarantors.

The following condensed consolidating financial data illustrates the composition of the combined guarantors. Investments in subsidiaries are accounted for by the parent using the equity method for purposes of the supplemental consolidating presentation. Earnings (losses) of subsidiaries are therefore reflected in the parent’s investment accounts and earnings. The principal elimination entries relate to investments in subsidiaries and intercompany balances and transactions.

QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED
(in thousands, unless otherwise indicated)
(unaudited)

Condensed Consolidating Statement of Operations
Three Months Ended June 30, 2009


	Parent			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated


Net revenues	$	230,634		$	1,560,418		$	198,806		$	(88,040	)	$	1,901,818

Operating costs and expenses:
Cost of services		144,405			894,932			60,875			—			1,100,212
Selling, general and administrative		51,704			309,371			95,337			(7,656	)		448,756
Amortization of intangible assets		21			7,777			1,579			—			9,377
Royalty (income) expense		(104,117	)		104,117			—			—			—
Other operating income, net		(15,217	)		(395	)		(290	)		—			(15,902	)

Total operating costs and expenses		76,796			1,315,802			157,501			(7,656	)		1,542,443

Operating income		153,838			244,616			41,305			(80,384	)		359,375
Non-operating (expense) income, net		(48,829	)		(73,781	)		4,667			80,384			(37,559	)

Income from continuing operations before taxes		105,009			170,835			45,972			—			321,816
Income tax expense		41,069			68,488			13,978			—			123,535

Income from continuing operations		63,940			102,347			31,994			—			198,281
Income from discontinued operations, net of taxes		—			88			—			—			88
Equity earnings from subsidiaries		124,260			—			—			(124,260	)		—

Net income		188,200			102,435			31,994			(124,260	)		198,369
Less: Net income attributable to noncontrolling interests		—			—			10,169			—			10,169

Net income attributable to Quest Diagnostics	$	188,200		$	102,435		$	21,825		$	(124,260	)	$	188,200

Condensed Consolidating Statement of Operations
Three Months Ended June 30, 2008


	Parent			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated


Net revenues	$	210,309		$	1,518,732		$	160,313		$	(51,453	)	$	1,837,901

Operating costs and expenses:
Cost of services		129,935			892,634			60,912			—			1,083,481
Selling, general and administrative		55,002			305,632			83,430			(6,027	)		438,037
Amortization of intangible assets		58			7,807			2,051			—			9,916
Royalty (income) expense		(107,694	)		107,694			—			—			—
Other operating expense (income), net		4			(49	)		(1,611	)		—			(1,656	)

Total operating costs and expenses		77,305			1,313,718			144,782			(6,027	)		1,529,778

Operating income		133,004			205,014			15,531			(45,426	)		308,123
Non-operating (expense) income, net		(39,262	)		(44,510	)		1,054			45,426			(37,292	)

Income from continuing operations before taxes		93,742			160,504			16,585			—			270,831
Income tax expense		32,462			64,408			3,917			—			100,787

Income from continuing operations		61,280			96,096			12,668			—			170,044
Loss from discontinued operations, net of taxes		—			(889	)		(1	)		—			(890	)
Equity earnings from subsidiaries		100,048			—			—			(100,048	)		—

Net income		161,328			95,207			12,667			(100,048	)		169,154
Less: Net income attributable to noncontrolling interests		—			—			7,826			—			7,826

Net income attributable to Quest Diagnostics	$	161,328		$	95,207		$	4,841		$	(100,048	)	$	161,328

QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED
(in thousands, unless otherwise indicated)
(unaudited)

Condensed Consolidating Statement of Operations
Six Months Ended June 30, 2009


	Parent			Subsidiary Guarantors			Non- Guarantor Subsidiaries		Eliminations			Consolidated


Net revenues	$	440,686		$	3,056,335		$	370,365	$	(157,562	)	$	3,709,824

Operating costs and expenses:
Cost of services		271,368			1,763,019			119,314		—			2,153,701
Selling, general and administrative		84,376			616,341			187,314		(14,974	)		873,057
Amortization of intangible assets		47			15,625			2,710		—			18,382
Royalty (income) expense		(200,457	)		200,457			—		—			—
Other operating (income) expense, net		(16,196	)		(184	)		626		—			(15,754	)

Total operating costs and expenses		139,138			2,595,258			309,964		(14,974	)		3,029,386

Operating income		301,548			461,077			60,401		(142,588	)		680,438
Non-operating (expense) income, net		(90,635	)		(130,245	)		7,186		142,588			(71,106	)

Income from continuing operations before taxes		210,913			330,832			67,587		—			609,332
Income tax expense		82,359			132,282			19,083		—			233,724

Income from continuing operations		128,554			198,550			48,504		—			375,608
Loss from discontinued operations, net of taxes		—			(1,583	)		—		—			(1,583	)
Equity earnings from subsidiaries		226,748			—			—		(226,748	)		—

Net income		355,302			196,967			48,504		(226,748	)		374,025
Less: Net income attributable to noncontrolling interests		—			—			18,723		—			18,723

Net income attributable to Quest Diagnostics	$	355,302		$	196,967		$	29,781	$	(226,748	)	$	355,302

Condensed Consolidating Statement of Operations
Six Months Ended June 30, 2008


	Parent			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated


Net revenues	$	407,728		$	2,999,331		$	330,469		$	(114,990	)	$	3,622,538

Operating costs and expenses:
Cost of services		249,737			1,768,897			123,474			—			2,142,108
Selling, general and administrative		97,244			618,406			169,381			(11,916	)		873,115
Amortization of intangible assets		113			15,725			3,342			—			19,180
Royalty (income) expense		(212,334	)		212,334			—			—			—
Other operating expense (income), net		4			(150	)		(103	)		—			(249	)

Total operating costs and expenses		134,764			2,615,212			296,094			(11,916	)		3,034,154

Operating income		272,964			384,119			34,375			(103,074	)		588,384
Non-operating (expense) income, net		(87,096	)		(98,102	)		4,177			103,074			(77,947	)

Income from continuing operations before taxes		185,868			286,017			38,552			—			510,437
Income tax expense		67,598			114,798			10,249			—			192,645

Income from continuing operations		118,270			171,219			28,303			—			317,792
Loss from discontinued operations, net of taxes		—			(1,624	)		(353	)		—			(1,977	)
Equity earnings from subsidiaries		182,665			—			—			(182,665	)		—

Net income		300,935			169,595			27,950			(182,665	)		315,815
Less: Net income attributable to noncontrolling interests		—			—			14,880			—			14,880

Net income attributable to Quest Diagnostics	$	300,935		$	169,595		$	13,070		$	(182,665	)	$	300,935

QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED
(in thousands, unless otherwise indicated)
(unaudited)

Condensed Consolidating Balance Sheet
June 30, 2009


	Parent		Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated

Assets
Current assets:
Cash and cash equivalents	$	55,623	$	14,507		$	49,164		$	—		$	119,294
Accounts receivable, net		10,038		168,265			718,232			—			896,535
Other current assets		55,040		164,846			105,644			(2,261	)		323,269

Total current assets		120,701		347,618			873,040			(2,261	)		1,339,098
Property, plant and equipment, net		196,710		611,905			35,142			—			843,757
Goodwill and intangible assets, net		153,169		5,293,836			439,582			—			5,886,587
Intercompany receivable (payable)		470,681		(263,868	)		(206,813	)		—			—
Investment in subsidiaries		5,540,994		—			—			(5,540,994	)		—
Other assets		153,830		18,483			48,439			(78,759	)		141,993

Total assets	$	6,636,085	$	6,007,974		$	1,189,390		$	(5,622,014	)	$	8,211,435


Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable and accrued expenses	$	505,061	$	255,580		$	60,527		$	(2,261	)	$	818,907
Short-term borrowings and current portion of long-term debt		—		2,956			202,013			—			204,969

Total current liabilities		505,061		258,536			262,540			(2,261	)		1,023,876
Long-term debt		2,309,805		222,037			345,925			—			2,877,767
Other liabilities		80,075		493,549			49,285			(78,759	)		544,150
Stockholders’ equity:
Quest Diagnostics stockholders’ equity		3,741,144		5,033,852			507,142			(5,540,994	)		3,741,144
Noncontrolling interests		—		—			24,498			—			24,498

Total stockholders’ equity		3,741,144		5,033,852			531,640			(5,540,994	)		3,765,642

Total liabilities and stockholders’ equity	$	6,636,085	$	6,007,974		$	1,189,390		$	(5,622,014	)	$	8,211,435

QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED
(in thousands, unless otherwise indicated)
(unaudited)

Condensed Consolidating Balance Sheet
December 31, 2008


	Parent		Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated

Assets
Current assets:
Cash and cash equivalents	$	218,565	$	6,715		$	28,666		$	—		$	253,946
Accounts receivable, net		4,426		134,005			694,442			—			832,873
Other current assets		52,407		262,952			98,631			(3,990	)		410,000

Total current assets		275,398		403,672			821,739			(3,990	)		1,496,819
Property, plant and equipment, net		211,847		631,921			35,919			—			879,687
Goodwill and intangible assets, net		153,213		5,303,312			425,804			—			5,882,329
Intercompany receivable (payable)		576,236		(184,426	)		(391,810	)		—			—
Investment in subsidiaries		5,323,173		—			—			(5,323,173	)		—
Other assets		179,222		33,301			39,951			(107,479	)		144,995

Total assets	$	6,719,089	$	6,187,780		$	931,603		$	(5,434,642	)	$	8,403,830


Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable and accrued expenses	$	552,094	$	628,958		$	42,557		$	(3,990	)	$	1,219,619
Short-term borrowings and current portion of long-term debt		—		2,886			2,256			—			5,142

Total current liabilities		552,094		631,844			44,813			(3,990	)		1,224,761
Long-term debt		2,498,342		245,472			334,275			—			3,078,089
Other liabilities		63,757		473,579			45,989			(107,479	)		475,846
Stockholders’ equity:
Quest Diagnostics stockholders’ equity		3,604,896		4,836,885			486,288			(5,323,173	)		3,604,896
Noncontrolling interests		—		—			20,238			—			20,238

Total stockholders’ equity		3,604,896		4,836,885			506,526			(5,323,173	)		3,625,134

Total liabilities and stockholders’ equity	$	6,719,089	$	6,187,780		$	931,603		$	(5,434,642	)	$	8,403,830

QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED
(in thousands, unless otherwise indicated)
(unaudited)

Condensed Consolidating Statement of Cash Flows
Six Months Ended June 30, 2009


	Parent			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated


Cash flows from operating activities:
Net income	$	355,302		$	196,967		$	48,504		$	(226,748	)	$	374,025
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		28,105			94,480			7,462			—			130,047
Provision for doubtful accounts		3,004			34,322			128,098			—			165,424
Other, net		(170,732	)		45,361			(3,455	)		226,748			97,922
Changes in operating assets and liabilities		(80,445	)		(289,358	)		(134,059	)		—			(503,862	)

Net cash provided by operating activities		135,234			81,772			46,550			—			263,556
Net cash provided by (used in) investing activities		167,271			(62,224	)		(1,056	)		(198,067	)		(94,076	)
Net cash used in financing activities		(465,447	)		(11,756	)		(24,996	)		198,067			(304,132	)

Net change in cash and cash equivalents		(162,942	)		7,792			20,498			—			(134,652	)
Cash and cash equivalents, beginning of period		218,565			6,715			28,666			—			253,946

Cash and cash equivalents, end of period	$	55,623		$	14,507		$	49,164		$	—		$	119,294

Condensed Consolidating Statement of Cash Flows
Six Months Ended June 30, 2008


	Parent			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated


Cash flows from operating activities:
Net income	$	300,935		$	169,595		$	27,950		$	(182,665	)	$	315,815
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization		25,736			97,370			9,578			—			132,684
Provision for doubtful accounts		5,788			57,873			103,907			—			167,568
Other, net		(161,572	)		16,914			(13,261	)		182,665			24,746
Changes in operating assets and liabilities		137,626			(270,297	)		(136,932	)		—			(269,603	)

Net cash provided by (used in) operating activities		308,513			71,455			(8,758	)		—			371,210
Net cash (used in) provided by investing activities		(124,134	)		(57,283	)		18,857			93,591			(68,969	)
Net cash used in financing activities		(198,160	)		(17,839	)		(16,847	)		(93,591	)		(326,437	)

Net change in cash and cash equivalents		(13,781	)		(3,667	)		(6,748	)		—			(24,196	)
Cash and cash equivalents, beginning of period		111,610			14,847			41,137			—			167,594

Cash and cash equivalents, end of period	$	97,829		$	11,180		$	34,389		$	—		$	143,398


Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations

Critical Accounting Policies

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions and select accounting policies that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

While many operational aspects of our business are subject to complex federal, state and local regulations, the accounting for our business is generally straightforward, with net revenues primarily recognized upon completion of the testing process. Our revenues are primarily comprised of a high volume of relatively low dollar transactions, and about one-half of total operating costs and expenses consist of employee compensation and benefits. Due to the nature of our business, several of our accounting policies involve significant estimates and judgments. These accounting policies have been described in our Annual Report on Form 10-K for the year ended December 31, 2008.

Results of Operations

Our clinical testing business currently represents our one reportable business segment. The clinical testing business accounted for more than 90% of net revenues from continuing operations in both 2009 and 2008. Our other operating segments consist of our risk assessment services business, our clinical trials testing business, our healthcare information technology business, MedPlus, and our diagnostic products business. Our business segment information is disclosed in Note 10 to the interim consolidated financial statements.

Three and Six Months Ended June 30, 2009 Compared with Three and Six Months Ended June 30, 2008

Continuing Operations

Income from continuing operations for the three months ended June 30, 2009 was $188 million, or $1.00 per diluted share, compared to $162 million, or $0.83 per diluted share, in 2008. Income from continuing operations for the six months ended June 30, 2009 was $357 million, or $1.89 per diluted share, compared to $303 million, or $1.54 per diluted share, in 2008. These increases in income from continuing operations were principally driven by improved operating performance and to a lesser degree by lower interest expense.

Results for the three and six months ended June 30, 2009 include a $15.5 million gain, or $0.05 per diluted share, associated with an insurance settlement for storm related losses, offset by a $6.3 million charge, or $0.02 per diluted share, associated with the early extinguishment of debt and a $7.0 million charge, or $0.02 per diluted share, associated with the write-down of an investment.

Net Revenues

Net revenues for the three months ended June 30, 2009 grew by 3.5% over the prior year level to $1.9 billion. Net revenues for the six months ended June 30, 2009 were $3.7 billion, 2.4% above the prior year level. Changes in foreign exchange rates reduced revenue growth for the three and six months ended June 30, 2009 by 0.7% and 0.8%, respectively.

For the second quarter of 2009, revenues for our clinical testing business, which accounts for over 90% of our net revenues, grew 4% above the prior year level. Pre-employment drug testing, which is part of the clinical testing business, reduced revenues by about 0.7%. Clinical testing volume, measured by the number of requisitions, decreased 0.6% for the quarter ended June 30, 2009. Pre-employment drug testing, which accounted for approximately 6% of our total clinical testing volume, declined 24% and reduced consolidated volume by 1.7%. The volume decrease in pre-employment drug testing is principally due to reduced hiring by employers served by this business. In addition, our decision to exit certain laboratory management agreements that did not meet our profitability thresholds reduced volume by 0.7%. Lastly, the second quarter of 2009 had fewer business days than the prior year which we estimate reduced volume by 0.6%. After giving consideration to these factors, underlying volume grew about 2.5% for the quarter ended June 30, 2009, up from approximately 1.5% growth in

the first quarter of 2009. Revenue per requisition increased 4.6% for the three months ended June 30, 2009, with the increase continuing to be primarily driven by a positive test mix and a benefit of about 0.5% from the Medicare laboratory fee increase which went into effect January 1, 2009.

For the six months ended June 30, 2009, clinical testing revenues grew 3.1% above the prior year level. Pre-employment drug testing reduced revenues by about 0.7%. Clinical testing volume, measured by the number of requisitions, decreased 1.2% for the six months ended June 30, 2009. Pre-employment drug testing, which accounted for 5% of our total clinical testing volume, declined 25% and reduced consolidated volume by 1.7%. The volume decrease in pre-employment drug testing is principally due to reduced hiring by employers served by this business. In addition, our decision to exit certain laboratory management agreements that did not meet our profitability thresholds reduced volume by 0.8%. Lastly, the six months ended June 30, 2009 had fewer business days than the prior year which we estimate reduced volume by 0.7%. After giving consideration to these factors, underlying volume grew about 2.0% for the six months ended June 30, 2009. Revenue per requisition increased 4.4% for the six months ended June 30, 2009, with the increase primarily driven by a positive test mix and a benefit of about 0.5% from the Medicare laboratory fee increase which went into effect January 1, 2009.

Our businesses other than clinical laboratory testing accounted for approximately 8% of our net revenues for the three and six months ended June 30, 2009. These businesses include our risk assessment services business, our clinical trials testing business, our healthcare information technology business, MedPlus, and our diagnostic products business. These businesses contain most of our international operations and, in the aggregate, reported revenues for the three and six ended June 30, 2009 were 1.8% and 4.7%, respectively, below the prior year periods, with the decline more than accounted for by the impact of foreign exchange rates which reduced the combined revenues of these businesses by approximately 6% and 7%, respectively, for the three and six months ended June 30, 2009.

Operating Costs and Expenses

Total operating costs and expenses for the three months ended June 30, 2009 increased $12.7 million compared to the second quarter of 2008, and decreased as a percentage of net revenues to 81% compared to 83% in 2008. Total operating costs and expenses for the six months ended June 30, 2009 decreased $4.8 million from the prior year period and decreased as a percentage of net revenues to 82% compared to 84% in 2008. Lower testing volume in our clinical testing business, actions we have taken to improve our operating efficiency and reduce the size of our workforce, and discrete cost containment actions taken during the first half of 2009 have enabled us to realize reduced costs year-to-date and a modest cost increase for the quarter on increased net revenues. These efforts, coupled with higher revenue per requisition, served to reduce operating costs and expenses as a percentage of net revenues.

Cost of services, which includes the costs of obtaining, transporting and testing specimens, was 57.9% of net revenues for the three months ended June 30, 2009, decreasing from 59.0% of net revenues in the prior year period. For the six months ended June 30, 2009, cost of services, as a percentage of net revenues, was 58.1% of net revenues, decreasing from 59.1% of net revenues in the prior year period. These improvements over the prior year reflect actions taken to reduce our cost structure and higher revenue per requisition.

Selling, general and administrative expenses, which include the costs of the sales force, billing operations, bad debt expense, and general management and administrative support, were 23.6% of net revenues for the three months ended June 30, 2009, compared to 23.8% in the prior year period. For the six months ended June 30, 2009, selling, general and administrative expenses, as a percentage of net revenues, decreased to 23.5% from 24.1% in the prior year period. These improvements were primarily due to actions taken to reduce our cost structure and higher revenue per requisition.

For both the three months ended June 30, 2009 and 2008, bad debt expense was 4.4% of net revenues. For the six months ended June 30, 2009, bad debt expense was 4.5% compared to 4.6% of net revenues in the prior year period. Continued progress in our billing and collection processes has resulted in stable bad debt, and improvements in days sales outstanding and the cost of our billing operation. With our disciplined approach, we expect to see continued strong performance in our billing and collection metrics, despite a slowing economy.

Other operating income, net represents miscellaneous income and expense items related to operating activities, including gains and losses associated with the disposal of operating assets and provisions for

restructurings and other special charges. For the three and six months ended June 30, 2009, other operating income, net includes a $15.5 million second quarter gain related to an insurance settlement for storm related losses.

Operating Income

Operating income for the three months ended June 30, 2009 was $359 million, or 18.9% of net revenues, compared to $308 million, or 16.8% of net revenues, in the prior year period. For the six months ended June 30, 2009, operating income was $680 million, or 18.3% of net revenues, compared to $588 million, or 16.2% of net revenues in the prior year period. The improvements in operating income, as a percentage of net revenues, were primarily due to a more profitable revenue mix, resulting in higher revenue per requisition and progress we are making with our cost reduction program, as well as discrete cost containment actions we took during the first quarter of 2009. In addition, operating income for the three and six months ended June 30, 2009 includes a $15.5 million gain related to an insurance settlement for storm related losses, which contributed approximately 80 basis points and 40 basis points, respectively, to the improvement in operating income as a percentage of net revenues. The operating income percentage for the three and six months ended June 30, 2009 also reflects the impact of the various items which served to reduce cost of services and selling, general and administrative expenses as a percentage of net revenues.

Other Income (Expense)

Interest expense, net for the three and six months ended June 30, 2009 decreased $9 million and $17 million, respectively, compared to the prior year periods. These decreases were primarily due to lower interest rates on our variable-interest rate debt, as well as lower average outstanding debt balances in the first half of 2009, compared to the prior year periods.

Other (expense) income, net represents miscellaneous income and expense items related to non-operating activities such as gains and losses associated with investments and other non-operating assets. For the three and six months ended June 30, 2009, other (expense) income, net includes a charge of $7.0 million associated with the write-down of an investment and a $6.3 million charge associated with the early extinguishment of debt.

Income Tax Expense

The effective income tax rate for the three and six months ended June 30, 2009 was above the prior year periods by 1.2% and 0.7%, respectively. These increases were primarily due to the favorable resolution of certain tax contingencies in the second quarter of 2008.

Discontinued Operations

Income from discontinued operations, net of taxes, for the three months ended June 30, 2009 was $0.1 million, or $0.00 per diluted share, compared to a loss of $0.9 million, or $0.01 per diluted share in 2008. Loss from discontinued operations, net of taxes, for the six months ended June 30, 2009 was $1.6 million, or $0.01 per diluted share, compared to $2.0 million, or $0.01 per diluted share in the prior year. On April 15, 2009, the Company finalized the resolution of the previously disclosed federal government investigation related to NID, a test kit subsidiary voluntarily closed in 2006, and entered into a settlement agreement with the federal government. In the second quarter of 2009, payments totaling $308 million, which had been previously reserved, were funded out of cash on-hand and available credit facilities. See Note 8 and Note 9 to the interim consolidated financial statements for further details.

Quantitative and Qualitative Disclosures About Market Risk

We address our exposure to market risks, principally the market risk of changes in interest rates, through a controlled program of risk management that includes the use of derivative financial instruments. We do not hold or issue derivative financial instruments for trading purposes. We believe that our exposures to foreign exchange impacts and changes in commodities prices are not material to our consolidated financial condition or results of operations. See Note 4 to the interim consolidated financial statements for additional discussion of our financial instruments and hedging activities.

At June 30, 2009 and December 31, 2008, the fair value of our debt was estimated at approximately $3.1 billion and $2.9 billion, respectively, using quoted market prices and yields for the same or similar types of borrowings, taking into account the underlying terms of the debt instruments. At June 30, 2009, the estimated fair

value exceeded the carrying value of the debt by $31 million. At December 31, 2008, the carrying value exceeded the estimated fair value of the debt by $155 million. A hypothetical 10% increase in interest rates on our total debt portfolio (representing approximately 45 and 53 basis points at June 30, 2009 and December 31, 2008, respectively) would potentially reduce the estimated fair value of our debt by approximately $66 million and $75 million at June 30, 2009 and December 31, 2008, respectively.

Borrowings under our senior unsecured revolving credit facility, our secured receivables credit facility and our term loan due May 2012 are subject to variable interest rates. Interest on our secured receivables credit facility is based on rates that are intended to approximate commercial paper rates for highly-rated issuers. Interest rates on our senior unsecured revolving credit facility and term loan due May 2012 are subject to a pricing schedule that can fluctuate based on changes in our credit ratings. As such, our borrowing costs under these credit arrangements will be subject to both fluctuations in interest rates and changes in our credit ratings. As of June 30, 2009, the borrowing rates under these credit facilities were: for our secured receivables credit facility, 1.28%; for our senior unsecured credit facility, LIBOR plus 0.40%; and for our term loan due May 2012, LIBOR plus 0.50%. At June 30, 2009, the weighted average LIBOR rate was 0.31%. At June 30, 2009, there was $1.1 billion outstanding under our term loan due May 2012, $200 million outstanding under our $500 million secured receivables credit facility and no borrowings outstanding under our $750 million senior unsecured revolving credit facility.

We have entered into various variable-to-fixed interest rate swap agreements, whereby we fixed the interest rates on a portion of our term loan due May 2012 for periods ranging through October 2009. As of June 30, 2009, variable-to-fixed interest rate swap agreements on $200 million of the term loan due May 2012 remain in place through October 2009 with fixed interest rates ranging from 5.13% to 5.27%. Based on our net exposure to interest rate changes, a hypothetical 10% change in interest rates on our variable rate indebtedness (representing approximately 5 basis points) would impact annual net interest expense by approximately $1 million, assuming no changes to the debt outstanding at June 30, 2009.

The fair value of the interest rate swap agreements at June 30, 2009 was a liability of $3.9 million. A hypothetical 10% increase or decrease in interest rates (representing approximately 8 basis points) would not have a material impact on the fair value of the liability of these instruments at June 30, 2009.

For details regarding our outstanding debt, see Note 5 to the interim consolidated financial statements and Note 9 to the Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2008. For details regarding our financial instruments, see Note 4 to the interim consolidated financial statements.

Risk Associated with Investment Portfolio

Our investment portfolio includes equity investments in publicly held companies that are classified as available-for-sale securities and other strategic equity holdings in privately held companies. These securities are exposed to price fluctuations and are generally concentrated in the life sciences industry. The carrying values of our available-for-sale equity securities and privately held securities were $8 million at June 30, 2009.

We regularly evaluate the fair value measurements of our equity investments to determine if losses in value are other than temporary and if an impairment loss has been incurred. The evaluation considers if the security has the ability to recover and, if so, the estimated recovery period. Other factors that are considered in this evaluation include the amount of the other-than-temporary decline and its duration, the issuer’s financial condition and short-term prospects and whether the market decline was caused by overall economic conditions or conditions specific to the individual security.

We do not hedge our equity price risk. The impact of an adverse movement in equity prices on our holdings in privately held companies cannot be easily quantified, as our ability to realize returns on investments depends on, among other things, the enterprises’ ability to raise additional capital or derive cash inflows from continuing operations or through liquidity events such as initial public offerings, mergers or private sales.

Fair Value Measurements

On January 1, 2008, we adopted Statement of Financial Accounting Standards (“SFAS”) No. 157, “Fair Value Measurements” (“SFAS 157”). Adoption of this accounting standard did not have a material effect on our financial position, results of operations or cash flows. See Note 2 to the interim consolidated financial statements for further details.

Liquidity and Capital Resources

Cash and Cash Equivalents

Cash and cash equivalents at June 30, 2009 totaled $119 million compared to $254 million at December 31, 2008. Cash and cash equivalents consist of highly liquid short-term investments, including time deposits with highly-rated banks, and various insured money market funds, including those that invest in U.S. Treasury securities. For the six months ended June 30, 2009, cash flows from operating activities of $264 million, together with cash on-hand, were used to fund investing and financing activities of $94 million and $304 million, respectively. Cash and cash equivalents at June 30, 2008 totaled $143 million, compared to $168 million at December 31, 2007. For the six months ended June 30, 2008, cash flows from operating activities of $371 million, together with cash on-hand, were used to fund investing and financing activities of $69 million and $326 million, respectively.

Cash Flows from Operating Activities

Net cash provided by operating activities for the six months ended June 30, 2009 was $264 million compared to $371 million in the prior year period. For the six months ended June 30, 2009, cash flows from operating activities includes second quarter 2009 payments totaling $308 million associated with the final settlement agreement related to the federal government’s investigation related to NID (see Note 8). After giving consideration to the settlement payments, underlying cash flows from operating activities exceeded the prior year level, primarily driven by higher earnings in the current year. Days sales outstanding, a measure of billing and collection efficiency, were 43 days at June 30, 2009 compared to 46 days at June 30, 2008 and 44 days at December 31, 2008.

Cash Flows from Investing Activities

Net cash used in investing activities for the six months ended June 30, 2009 was $94 million, consisting principally of capital expenditures of $76 million.

Net cash used in investing activities for the six months ended June 30, 2008 was $69 million, consisting principally of capital expenditures of $95 million, partially offset by $23 million related to the receipt of a payment from an escrow fund established at the time of an acquisition in 2007, and proceeds from the sale of an investment in the first quarter of 2008.

Cash Flows from Financing Activities

Net cash used in financing activities for the six months ended June 30, 2009 was $304 million, consisting primarily of purchases of treasury stock totaling $250 million, dividend payments of $38 million and a decrease in book overdrafts of $20 million, partially offset by $19 million in proceeds from the exercise of stock options, including related tax benefits. The $250 million of treasury stock purchases represents 5.6 million shares of our common stock purchased at an average price of $44.48 per share. Cash flows from financing activities for the six months ended June 30, 2009 also included a net reduction of debt of $1 million, consisting of $510 million of borrowings and $511 million of repayments. Borrowings under our secured receivables credit facility totaled $510 million and were used primarily to fund the NID settlement payments totaling $308 million and $150 million to fund the retirement of debt in connection with our June 2009 debt tender. Debt repayments of $511 million consisted primarily of the repayment of $310 million on our secured receivables credit facility, and $174 million aggregate principal amount of our 5.125% senior notes due 2010 and $26 million aggregate principal amount of our 7.50% senior notes due 2011.

Net cash used in financing activities for the six months ended June 30, 2008 was $326 million, consisting primarily of net reductions of debt of $284 million and dividend payments of $39 million. Net debt reductions

included the repayment of $168 million on our term loan due May 31, 2012, $120 million on our secured receivables credit facility and $15 million on our term loan due December 31, 2008, offset partially by borrowings of $20 million on our secured receivables credit facility.

Dividend Program

During each of the quarters of 2009 and 2008, our Board of Directors declared a quarterly cash dividend of $0.10 per common share. On May 14, 2009, our Board of Directors declared a quarterly cash dividend per common share of $0.10, paid on July 20, 2009. We expect to fund future dividend payments with cash flows from operations, and do not expect the dividend to have a material impact on our ability to finance future growth.

Share Repurchase Plan

In January 2009, our Board of Directors authorized $500 million of additional share repurchases. The share repurchase authorization has no set expiration or termination date. We did not repurchase any shares of our common stock during the three months ended June 30, 2009. For the six months ended June 30, 2009, we repurchased 5.6 million shares of our common stock at an average price of $44.48 per share for $250 million, including 4.5 million shares repurchased from SB Holdings Capital Inc., a wholly-owned subsidiary of GlaxoSmithKline plc., at an average price of $44.33 per share for $200 million. For the three and six months ended June 30, 2009, the Company reissued 0.4 million shares and 0.9 million shares, respectively, for employee benefit plans. Since its inception in May 2003, we have repurchased approximately 55 million shares of our common stock at an average price of $45.33 for $2.5 billion under our share repurchase program. At June 30, 2009, $250 million of share repurchase authorization remained available.

Contractual Obligations and Commitments

The following table summarizes certain of our contractual obligations as of June 30, 2009:


	Payments due by period

	(in thousands)
Contractual Obligations	Total		Remainder of 2009		1-3 years		3 –5 years		After 5 years


Outstanding debt	$	3,065,525	$	201,800	$	1,006,675	$	560,000	$	1,297,050
Capital lease obligations		17,211		1,566		3,222		1,974		10,449
Interest payments on outstanding debt		1,305,062		66,399		236,214		166,289		836,160
Operating leases		713,194		98,601		285,005		139,235		190,353
Purchase obligations		110,218		29,369		69,984		10,396		469

Total contractual obligations	$	5,211,210	$	397,735	$	1,601,100	$	877,894	$	2,334,481

Interest payments on our outstanding debt have been calculated after giving effect to our interest rate swap agreements, using the interest rates as of June 30, 2009 applied to the June 30, 2009 balances, which are assumed to remain outstanding through their maturity dates.

A full description of the terms of our indebtedness and related debt service requirements and our future payments under certain of our contractual obligations is contained in Note 9 to the Consolidated Financial Statements in our 2008 Annual Report on Form 10-K. A full discussion and analysis regarding our minimum rental commitments under noncancelable operating leases and noncancelable commitments to purchase products or services at December 31, 2008 is contained in Note 14 to the Consolidated Financial Statements in our 2008 Annual Report on Form 10-K.

As of June 30, 2009, our total liabilities for unrecognized tax benefits were approximately $120 million, which were excluded from the table above. The increase in liabilities for unrecognized tax benefits since December 31, 2008 is primarily due to certain unrecognized tax benefits of $57 million associated with the NID settlement. We believe it is reasonably possible that our liabilities for unrecognized tax benefits may decrease by approximately $5 million within the next twelve months, primarily as a result of the expiration of statues of limitations, settlements and/or the conclusion of tax examinations on certain tax positions. For the remainder, we cannot make reasonably reliable estimates of the timing of the future payments of these liabilities. See Note 4 to

the Consolidated Financial Statements in our 2008 Annual Report on Form 10-K for information regarding our contingent tax liability reserves.

Our credit agreements and our term loan due May 2012 contain various covenants and conditions, including the maintenance of certain financial ratios, that could impact our ability to, among other things, incur additional indebtedness. As of June 30, 2009, we were in compliance with the various financial covenants included in our credit agreements and we do not expect these covenants to adversely impact our ability to execute our growth strategy or conduct normal business operations.

Unconsolidated Joint Ventures

We have investments in unconsolidated joint ventures in Phoenix, Arizona; Indianapolis, Indiana; and Dayton, Ohio, which are accounted for under the equity method of accounting. We believe that our transactions with our joint ventures are conducted at arm’s length, reflecting current market conditions and pricing. Total net revenues of our unconsolidated joint ventures equal less than 6% of our consolidated net revenues. Total assets associated with our unconsolidated joint ventures are less than 2% of our consolidated total assets. We have no material unconditional obligations or guarantees to, or in support of, our unconsolidated joint ventures and their operations.

Requirements and Capital Resources

We estimate that we will invest approximately $200 million during 2009 for capital expenditures to support and expand our existing operations, principally related to investments in information technology, equipment, and facility upgrades.

As of June 30, 2009, $1.1 billion of borrowing capacity was available under our existing credit facilities, consisting of $300 million available under our secured receivables credit facility and $750 million available under our senior unsecured revolving credit facility. Our secured receivables credit facility matures on December 11, 2009. If we are unable to refinance or extend the term of our current secured receivables credit facility, we may need to utilize our senior unsecured revolving credit facility or seek additional financing through other financing arrangements.

We believe the banks participating in our various credit facilities are predominantly highly-rated banks, and that the amounts under the credit facilities are currently available to us. Should one or several banks no longer participate in either of our credit facilities, we would not expect it to impact our ability to fund operations. We expect to continue to generate positive cash flow despite a slowing economy.

We believe that cash and cash equivalents on-hand and cash from operations, together with our borrowing capacity under our credit facilities, will provide sufficient financial flexibility to meet seasonal working capital requirements and to fund capital expenditures, debt service requirements, cash dividends on common shares, share repurchases and additional growth opportunities for the foreseeable future. We believe that our credit profile should provide us with access to additional financing, if necessary, to fund growth opportunities that cannot be funded from existing sources.

Impact of New Accounting Standards

In April 2009, the Financial Accounting Standards Board (“FASB”) issued FASB Staff Position No. FAS 107-1 and APB 28-1, “Interim Disclosures about Fair Value of Financial Instruments.” In June 2009, the FASB issued Statement of Financial Accounting Standards (“SFAS”) No. 165, “Subsequent Events,” and SFAS No. 167, “Amendments to FASB Interpretation No. 46(R).” The impact of these accounting standards is discussed in Note 1 to the interim consolidated financial statements.

Forward-Looking Statements

Some statements and disclosures in this document are forward-looking statements. Forward-looking statements include all statements that do not relate solely to historical or current facts and can be identified by the use of words such as “may,” “believe,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan” or “continue”. These forward-looking statements are based on our current plans and expectations and are subject to a number of risks and uncertainties that could significantly cause our plans and expectations, including actual results, to differ materially from the forward-looking statements. Risks and uncertainties that may affect our future results include,

but are not limited to, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, changes in government regulations, changing relationships with customers, payers, suppliers and strategic partners and other factors discussed in “Business” in Part I, Item 1, “Risk Factors” and “Cautionary Factors That May Affect Future Results” in Item I, Part 1A, “Legal Proceedings” in Part I, Item 3, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part II, Item 7 and “Quantitative and Qualitative Disclosures About Market Risk” in Part II, Item 7A in our 2008 Annual Report on Form 10-K and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Quantitative and Qualitative Disclosures About Market Risk” and “Risk Factors” in Part II, Item 1A in our 2009 Quarterly Reports on Form 10-Q and other items throughout the 2008 Form 10-K and our 2009 Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.


Item 3.	Quantitative and Qualitative Disclosures About Market Risk

See Item 2. “Management’s Discussion and Analysis of Financial Condition and Results of Operations”.


Item 4.	Controls and Procedures


(a)	Under the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, we have evaluated the effectiveness of our disclosure controls and procedures (as defined under Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended). Based upon that evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this quarterly report.

(b)	During the second quarter of 2009, there were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended) that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION


Item 1.	Legal Proceedings

See Note 8 to the interim consolidated financial statements for information regarding the status of legal proceedings involving the Company.


Item 1A.	Risk Factors

In addition to the risk factors set forth in Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2008, investors should consider the following risk factor before deciding to invest in any securities issued by the Company.

If we fail to comply with the requirements of our corporate integrity agreement, we could be subject to suspension or termination from participation in federal healthcare programs and substantial monetary penalties.

As part of a settlement with the U.S. Department of Justice and other federal government agencies, in April 2009 the Company entered into a five-year Corporate Integrity Agreement with the U.S. Department of Health and Human Services Office of Inspector General. The Corporate Integrity Agreement provides, among other things, that the Company continue to maintain a compliance program, overseen by the Company’s Board of Directors, regarding federal healthcare program requirements and FDA requirements, including written policies and procedures, a written Code of Conduct and employee training and education. The Company is subject to periodic reporting, external review and certification requirements regarding compliance with the Corporate Integrity Agreement. Failure of the Company to comply with the obligations under the Corporate Integrity Agreement could result in exclusion from participation in certain federal healthcare programs, financial penalties and damage to the Company’s reputation.


Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds

The table below sets forth the information with respect to purchases made by or on behalf of the Company of its common stock during the second quarter of 2009.

ISSUER PURCHASES OF EQUITY SECURITIES


Period	Total Number of Shares Purchased		Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs		Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs (in thousands)

April 1, 2009 – April 30, 2009
Share Repurchase Program (A)		—	$	—		—	$	250,041
Employee Transactions (B)		124	$	50.56		N/A		N/A
May 1, 2009 – May 31, 2009
Share Repurchase Program (A)		—	$	—		—	$	250,041
Employee Transactions (B)		9,957	$	50.92		N/A		N/A
June 1, 2009 – June 30, 2009
Share Repurchase Program (A)		—	$	—		—	$	250,041
Employee Transactions (B)		178	$	52.77		N/A		N/A
Total
Share Repurchase Program (A)		—	$	—		—	$	250,041
Employee Transactions (B)		10,259	$	50.95		N/A		N/A


(A)	In January 2009, our Board of Directors authorized the Company to repurchase an additional $500 million of the Company’s common stock. Since the share repurchase program’s inception in May 2003, our Board of Directors has authorized $2.8 billion of share repurchases of our common stock through June 30, 2009. The share repurchase authorization has no set expiration or termination date.

(B)	Includes: (1) shares delivered or attested to in satisfaction of the exercise price and/or tax withholding obligations by holders of stock options (granted under the Company’s Amended and Restated Employee Long-Term Incentive Plan and its Amended and Restated Non-Employee Director Long-Term Incentive Plan, collectively the “Stock Compensation Plans”) who exercised options; (2) restricted common shares withheld (under the terms of grants under the Stock Compensation Plans) to offset tax withholding obligations that occur upon vesting and release of the restricted common shares; and (3) shares withheld (under the terms of grants under the Stock Compensation Plans) to offset tax withholding obligations that occur upon the delivery of common shares underlying restricted stock units and performance share units.


Item 4.	Submission of Matters to a Vote of Security Holders


(a)	The Annual Meeting of Shareholders of the Company was held on May 14, 2009. At the meeting, the matters described below were approved by the shareholders.

(b)	The following nominees for the office of director were elected for terms expiring at the 2012 Annual Meeting of Shareholders, by the following votes:


	For		Against		Abstain

Jenne K. Britell, Ph.D.		163,343,417		4,198,266		396,745

Gail R. Wilensky, Ph.D.		161,639,429		5,879,270		419,872

Mr. John B. Ziegler		161,586,592		5,916,218		435,613


	The following persons continue as directors:

	John C. Baldwin, M.D.
	Mr. William F. Buehler
	Ms. Rosanne Haggerty
	Surya N. Mohapatra, Ph.D.
	Mr. Gary M. Pfeiffer
	Daniel C. Stanzione, Ph.D.


(c)	The amendments to the Employee Long-Term Incentive Plan were approved by the following votes:


For	Against	Abstain	Broker Non-Vote
141,605,222	14,803,576	413,435	11,116,338


(d)	The amendments to the Long-Term Incentive Plan for Non-Employee Directors were approved by the following votes:


For	Against	Abstain	Broker Non-Vote
142,281,233	13,816,658	724,343	11,116,337


(e)	The ratification of the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm to audit the financial statements of the Company and its subsidiaries for the fiscal year ending December 31, 2009, was approved by the following votes:


For	Against	Abstain
165,510,615	2,143,193	284,625


Item 6.	Exhibits

	Exhibits:

		10.1	Amendment dated June 26, 2009 to the Stockholders Agreement dated as of August 16, 1999 between Quest Diagnostics Incorporated and SmithKline Beecham plc

		31.1	Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

		31.2	Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

		32.1	Certification of Chief Executive Officer Pursuant to 18 U.S.C. §1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

		32.2	Certification of Chief Financial Officer Pursuant to 18 U.S.C. §1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

		101.INS	dgx-20090630.xml

		101.SCH	dgx-20090630.xsd

		101.CAL	dgx-20090630_cal.xml

		101.DEF	dgx-20090630_def.xml

		101.LAB	dgx-20090630_lab.xml

		101.PRE	dgx-20090630_pre.xml

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

July 28, 2009
Quest Diagnostics Incorporated


By	/s/	Surya N. Mohapatra

		Surya N. Mohapatra, Ph.D.
		Chairman of the Board, President and
		Chief Executive Officer

By	/s/	Robert A. Hagemann

		Robert A. Hagemann
		Senior Vice President and
		Chief Financial Officer